🇺🇸 PTCT — PTC Therapeutics, Inc.

Salud Compra
← Volver

Precio actual

68,12 USD

Máx. histórico

89,55

117 días

Caída desde máximo

-23,93%

Rango 52 semanas

58,80 – 90,87

Variación hoy

+11,89%

Cierre anterior

60,88

Rango de hoy

63,16 – 68,72

Volumen hoy

2.643.738

Peor caída histórica

-94,60%

17/03/2015 → 03/11/2016

Recuperado en 3305 días

Volatilidad anualizada ⓘ

72,99%

Información
Nombre completo
PTC Therapeutics, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
991
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
100,47 USD (puede no estar actualizado)
Primera cotización
20/06/2013
Precio actualizado
hace 9 horas
Sobre la empresa

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
15/04/2025 44,85 48,60 44,58 46,94 +4,13% 8,96% 1.584.000
14/04/2025 43,99 45,76 42,84 45,08 +4,89% 6,64% 958.000
11/04/2025 40,28 43,54 39,03 42,98 +6,68% 11,20% 1.488.800
10/04/2025 41,00 41,82 38,70 40,29 -5,75% 7,60% 1.019.400
09/04/2025 38,87 44,07 37,32 42,75 +7,49% 17,37% 1.605.000
08/04/2025 44,00 45,03 38,86 39,77 -7,12% 14,02% 1.801.600
07/04/2025 41,79 44,99 40,86 42,82 -0,97% 9,88% 1.279.100
04/04/2025 45,44 46,16 42,98 43,24 -7,47% 7,00% 1.309.500
03/04/2025 46,88 48,10 45,76 46,73 -3,39% 4,99% 988.000
02/04/2025 45,97 48,95 45,44 48,37 +3,80% 7,64% 1.262.600
01/04/2025 50,73 51,43 46,37 46,60 -8,56% 9,97% 2.883.800
31/03/2025 52,89 52,89 45,40 50,96 -6,05% 14,16% 1.918.800
28/03/2025 54,09 55,29 53,53 54,24 -1,36% 3,24% 604.900
27/03/2025 55,79 56,00 54,86 54,99 -0,58% 2,04% 403.200
26/03/2025 56,20 56,20 54,26 55,31 -1,71% 3,45% 613.300
25/03/2025 56,88 56,95 55,57 56,27 -1,33% 2,43% 1.242.900
24/03/2025 57,97 57,97 56,14 57,03 -0,19% 3,16% 1.003.500
21/03/2025 56,25 57,34 55,73 57,14 +0,90% 2,86% 1.038.000
20/03/2025 56,40 57,56 56,23 56,63 -0,61% 2,35% 460.000
19/03/2025 55,09 57,42 55,00 56,98 +2,72% 4,39% 640.800
18/03/2025 56,54 57,20 55,11 55,47 -2,97% 3,69% 606.500
17/03/2025 54,17 58,38 54,06 57,17 +4,90% 7,97% 828.100
14/03/2025 53,50 55,65 53,09 54,50 +3,30% 4,79% 861.900
13/03/2025 52,89 54,65 51,93 52,76 -1,59% 5,15% 613.300
12/03/2025 53,00 53,76 52,26 53,61 +1,94% 2,83% 837.400
11/03/2025 53,12 53,19 50,65 52,59 +0,19% 4,78% 860.700
10/03/2025 52,00 53,82 51,73 52,49 -0,19% 4,02% 1.130.300
07/03/2025 52,92 53,79 51,59 52,59 -0,40% 4,16% 1.214.000
06/03/2025 51,42 52,83 50,29 52,80 +1,68% 4,94% 801.700
05/03/2025 51,66 52,47 50,93 51,93 +0,25% 2,98% 881.200